Profile data is unavailable for this security.
About the company
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a China-based company principally engaged in the research, development, manufacturing and retail of Chinese herbal medicines, Chinese patent medicines, chemical raw materials and preparations, and nutritional health products. The Company operates its businesses through three segments. The Chinese Patent Medicine segment is mainly engaged in the research, development, manufacturing and sales of Chinese medicines, including Su Xiao Jiu Xin Pill, Jing Wan Hong Ruan Gao, An Gong Niu Huang Pill, Qing Gong Shou Tao Pill and other products. The Western Medicine segment is mainly engaged in the research, development, manufacturing and sales of Western medicines. The Others segment mainly includes economic information consulting services, house leasing and other businesses. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in USD (TTM)784.35m
- Net income in USD522.98m
- Incorporated1981
- Employees11.00k
- LocationTianjin Pharmaceutical Da Ren Tang Group Corp LtdNo. 17, Baidi Road, Nankai DistrictTIANJIN 300193ChinaCHN
- Phone+86 2 227020892
- Fax+86 2 227020892
- Websitehttps://www.jydrt.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ajanta Pharma Ltd | 571.13m | 111.40m | 4.11bn | 9.63k | 36.87 | -- | 31.64 | 7.19 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| Simcere Pharmaceutical Group Ltd | 1.04bn | 128.67m | 4.11bn | 6.82k | 30.30 | 3.71 | 22.84 | 3.96 | 0.4092 | 0.4092 | 3.29 | 3.34 | 0.5845 | 2.20 | 2.81 | 1,234,348.00 | 7.24 | 8.74 | 9.93 | 12.42 | 81.00 | 78.53 | 12.39 | 15.60 | 1.57 | 4.72 | 0.1453 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| Hikma Pharmaceuticals Plc | 3.35bn | 485.05m | 4.16bn | 9.31k | 8.13 | 1.52 | 5.92 | 1.24 | 1.62 | 1.62 | 11.15 | 8.67 | 0.62 | 1.81 | 3.33 | -- | 9.07 | 7.02 | 13.34 | 9.82 | 43.51 | 47.60 | 14.63 | 11.45 | 1.06 | 7.14 | 0.381 | 41.87 | 6.12 | 7.42 | 35.10 | 2.39 | 7.19 | -1.07 |
| IPCA Laboratories Ltd | 1.04bn | 99.90m | 4.26bn | 18.04k | 42.63 | -- | 28.55 | 4.08 | 35.86 | 35.86 | 374.66 | -- | -- | -- | -- | 5,267,716.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 9.97 | 11.25 | -- | 19.58 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 784.35m | 522.98m | 4.30bn | 11.00k | 5.26 | 2.09 | 7.99 | 5.48 | 0.6791 | 0.6791 | 1.02 | 1.71 | 0.4758 | 1.35 | 2.47 | -- | 31.64 | 11.74 | 45.05 | 16.71 | 64.27 | 41.33 | 66.50 | 14.81 | 2.33 | -- | 0.0023 | 60.77 | -11.14 | 0.8791 | 125.94 | 28.94 | -10.54 | 31.80 |
| Anthem BioSciences Ltd | 219.22m | 53.21m | 4.32bn | 2.06k | 81.64 | -- | 64.62 | 19.73 | 8.59 | 8.59 | 35.40 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.34bn | 8.10k | 835.96 | -- | 14.56 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Xuanzhu Biopharmaceutical Co Ltd | 4.67m | -81.33m | 4.37bn | 197.00 | -- | 35.34 | -- | 935.40 | -1.23 | -1.23 | 0.0706 | 1.87 | -- | -- | -- | -- | -- | -- | -- | -- | 41.02 | -- | -1,740.97 | -- | 1.10 | -- | 0.0013 | -- | 103,672.40 | -- | -85.13 | -- | -- | -- |
| Xiamen Amoytop Biotech Co Ltd | 487.30m | 137.00m | 4.47bn | 2.42k | 32.53 | 10.16 | -- | 9.18 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Shanghai Junshi Biosciences Co Ltd | 362.05m | -138.50m | 4.48bn | 2.67k | -- | 5.62 | -- | 12.37 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Phillip Capital Management (S) Ltd.as of 30 Jun 2025 | 157.40k | 0.08% |
| E Fund Management (Hong Kong) Co., Ltd.as of 30 Jun 2025 | 152.60k | 0.08% |
| Mellon Investments Corp.as of 31 Dec 2025 | 19.50k | 0.01% |
| Northern Trust Investments, Inc.(Investment Management)as of 06 Feb 2026 | 4.90k | 0.00% |
| Franklin Advisory Services LLCas of 06 Feb 2026 | 2.00k | 0.00% |
| State Street Global Advisors, Australia, Ltd.as of 06 Feb 2026 | 1.50k | 0.00% |
